Use of fucoidan of sporophylls of undaria pinnatifida in preparation of uric acid-lowering or gout-treating products
Fucoidan from wakame spore leaves addresses the issue of significant side effects associated with existing medications by inhibiting uric acid transport proteins and assisting in the inhibition of xanthine oxidase, thus achieving safe and effective uric acid regulation and gout relief.
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- DALIAN HAIBAO BIOTECHNOLOGY CO LTD
- Filing Date
- 2025-08-12
- Publication Date
- 2026-06-04
AI Technical Summary
Existing uric acid-lowering drugs have significant side effects and are unsafe for long-term use. Furthermore, a low-purine diet has limited effect on uric acid regulation and cannot effectively prevent or treat hyperuricemia and gout.
Using fucoidan (MF) from wakame spore leaves as the active ingredient, it increases uric acid excretion by inhibiting the renal uric acid transport proteins URAT1 and GLUT9, and helps to inhibit hepatic xanthine oxidase, thereby reducing uric acid levels, and can be prepared into pharmaceuticals, health foods and food products.
Fucoidan from wakame spore leaves is safe and non-toxic, significantly reduces serum uric acid levels, decreases the frequency and severity of gout attacks, and provides a safe and effective uric acid-lowering solution.
Smart Images

Figure CN2025114081_04062026_PF_FP_ABST